Trial site
Haifa
- 20running trials
- 6closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Conditions
- Coronary artery disease3 trials
- Lupus (SLE)3 trials
- Multiple sclerosis3 trials
- Prostate cancer3 trials
- Stroke3 trials
- Colorectal cancer2 trials
- IgA nephropathy2 trials
- Lung cancer2 trials
- ANCA-associated vasculitis1 trial
- Aortic stenosis1 trial
- Chronic myeloid leukaemia1 trial
- Dermatomyositis and polymyositis (myositis)1 trial
- and 10 more
- Phase
- Phase 313 trials
- Phase 210 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Active, not recruiting12 trials
- Recruiting8 trials
- Completed4 trials
- Terminated2 trials
- Lead sponsor
- Novartis Pharmaceuticals26 trials
Running trials
Active, not recruiting
Recruiting
Recruiting
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Active, not recruiting
Active, not recruiting
Active, not recruiting
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- IgA nephropathy2 recruiting
- Lung cancer2 recruiting
- Prostate cancer2 recruiting
- Aortic stenosis1 recruiting
- Colorectal cancer1 recruiting
- Metastatic breast cancer1 recruiting
- Multiple sclerosis1 recruiting
- Pancreatic cancer1 recruiting
- Sarcoma1 recruiting
- Triple-negative breast cancer1 recruiting
Closed trials
Terminated
Completed
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
Completed
Terminated
Completed
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Completed
Site data: ClinicalTrials.govUpdated 17 Nov 2026